Protein Phosphatase 2A as a Therapeutic Target in Pulmonary Diseases
New disease targets and medicinal chemistry approaches are urgently required to develop novel therapeutic techniques for treating lung illnesses. Emerging evidence shows that reduced activity of protein phosphatase 2A (PP2A), an intricate heterotrimeric enzyme that regulates dephosphorylation of serine and threonine residues from many proteins, is noted in multiple lung illnesses, including cancer of the lung, smoke-caused chronic obstructive lung disease, alpha-1 antitrypsin deficiency, bronchial asthma, and idiopathic lung fibrosis. Lack of PP2A responses is related to a lot of mechanisms connected with disease progressions, for example senescence, proliferation, inflammation, corticosteroid resistance, enhanced protease responses, and mRNA stability. Therefore, chemical restoration of PP2A may represent a singular strategy to these illnesses. This review outlines the possibility impact of reduced PP2A activity in lung illnesses, endogenous and exogenous inhibitors of PP2A, details the potential PP2A-dependent mechanisms noticed in these conditions, and descriptions potential therapeutic techniques for treatment. Substantial medicinal chemistry attempts are going ahead to build up therapeutics targeting PP2A activity. The introduction of specific activators of PP2A that selectively target PP2A holoenzymes could improve our knowledge of the part of PP2A in lung illnesses. This leads to the DT-061 introduction of therapeutics for restoring normal PP2A responses inside the lung.